Iscartrelvir is an investigational new drug developed by the Westlake University for the treatment of COVID-19.

It targets the SARS-CoV-2 3CL protease, which is crucial for the replication of the virus responsible for COVID-19.

[1][2]

This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.